These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 12457130)

  • 21. The treatment of deep venous thrombosis, including the newer agents.
    Rectenwald JE; Wakefield TW
    Dis Mon; 2005; 51(2-3):104-11. PubMed ID: 15900261
    [No Abstract]   [Full Text] [Related]  

  • 22. [Initial results of the PROTECT Study publicized. Stroke patients need effective thrombosis prevention].
    Diener HC
    MMW Fortschr Med; 2005 Jun; 147(22):50. PubMed ID: 15977636
    [No Abstract]   [Full Text] [Related]  

  • 23. The role of low-molecular-weight heparins in treating thrombosis.
    Lee AY
    J Support Oncol; 2006 Mar; 4(3):123-4. PubMed ID: 16553137
    [No Abstract]   [Full Text] [Related]  

  • 24. A benchmark for platelet count monitoring with low-molecular-weight heparin: expanding implementation of National Patient Safety Goals.
    Spinler SA
    Ann Pharmacother; 2009 Sep; 43(9):1519-21. PubMed ID: 19690223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Anticoagulation of the extracorporeal circuit in chronic hemodialysis].
    Ryckelynck JP; Chouraqui D; Lobbedez T
    Nephrologie; 1998; 19(4):223-5. PubMed ID: 9675763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low molecular weight heparins: practical considerations.
    Kessler CM
    Semin Hematol; 1997 Oct; 34(4 Suppl 4):35-42. PubMed ID: 9399408
    [No Abstract]   [Full Text] [Related]  

  • 27. So, does low-molecular-weight heparin cause less heparin-induced thrombocytopenia than unfractionated heparin or not?
    Warkentin TE; Greinacher A
    Chest; 2007 Oct; 132(4):1108-10. PubMed ID: 17934108
    [No Abstract]   [Full Text] [Related]  

  • 28. [Heparins, antivitamins K. Principles and rules for their use. Dosage of non-fractionated heparins].
    Sié P
    Rev Prat; 1998 Jun; 48(12):1361-5. PubMed ID: 9781198
    [No Abstract]   [Full Text] [Related]  

  • 29. Venous thromboembolism: a guide to prevention and treatment.
    Crowther M; McCourt K
    Nurse Pract; 2005 Aug; 30(8):26-9, 32-4, 39-43; quiz 44-5. PubMed ID: 16094200
    [No Abstract]   [Full Text] [Related]  

  • 30. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis.
    Greaves M;
    Thromb Haemost; 2002 Jan; 87(1):163-4. PubMed ID: 11848446
    [No Abstract]   [Full Text] [Related]  

  • 31. Low molecular weight heparin and bleeding in patients with chronic renal failure.
    Crowther M; Lim W
    Curr Opin Pulm Med; 2007 Sep; 13(5):409-13. PubMed ID: 17940486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The cardiologist and anticoagulants: the heart has its reasons].
    Montalescot G; Grosgogeat Y
    Presse Med; 1992 Mar; 21(9):409-12. PubMed ID: 1314377
    [No Abstract]   [Full Text] [Related]  

  • 33. [Low molecular weight heparin--a safer anticoagulant in thrombosis and cancer].
    Schulman S
    Lakartidningen; 2004 May; 101(19):1712-5. PubMed ID: 15188585
    [No Abstract]   [Full Text] [Related]  

  • 34. Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?
    Ferretti G; Bria E; Giannarelli D; Carlini P; Felici A; Mandala M; Papaldo P; Nistico C; Fabi A; Cuppone F; Gelibter A; Terzoli E; Cognetti F
    J Clin Oncol; 2005 Oct; 23(28):7248-50; author reply 7250. PubMed ID: 16192623
    [No Abstract]   [Full Text] [Related]  

  • 35. [What are the safety measures for use of low-molecular-weight heparins in the treatment of deep venus thrombosis?].
    Fiessinger JN
    Presse Med; 2000 Apr; 29(13):766-8. PubMed ID: 10797834
    [No Abstract]   [Full Text] [Related]  

  • 36. New strategies in anti-thrombotic therapy offer efficacy, cost savings.
    Clin Resour Manag; 2001 Oct; 2(10):155-8, 145. PubMed ID: 11682931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Low-molecular weight heparin in the treatment of pregnant women with high thrombotic risk].
    Todorova K; Mazneĭkova V; Ivanov S
    Akush Ginekol (Sofiia); 2004; 43(4):46-52. PubMed ID: 15318544
    [No Abstract]   [Full Text] [Related]  

  • 38. [Use of low-molecular-weight heparins in patients with prosthetic heart valves].
    Hering D; Horstkotte D
    Dtsch Med Wochenschr; 2003 May; 128(20):1129-33. PubMed ID: 12748904
    [No Abstract]   [Full Text] [Related]  

  • 39. [Perioperative heparin bridging is rarely indicated].
    Nielsen JD; Münster AM; Husted SE
    Ugeskr Laeger; 2016 Feb; 178(9):V12150952. PubMed ID: 26957485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perioperative bridging therapy for the at-risk patient on chronic anticoagulation.
    Spyropoulos AC
    Dis Mon; 2005; 51(2-3):183-93. PubMed ID: 15900271
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.